# US 2023/0271971 A1 · Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271971 A1
- Document ID: US20230271971A1
- Status: Published application
- Kind: A1
- Application number: 18/077,466
- Filed: 2022-12-08
- Published: 2023-08-31
- Earliest claimed: 2019-04-12
- Assignees: Blueprint Medicines Corporation
- Applicants: Blueprint Medicines Corporation
- Inventors: Joshua D. Waetzig; Gordon Wilkie
- Web page: https://patentgrep.com/patent/US20230271971A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.

## Claims

### Claim 1

Crystalline Form A of Compound (I):
characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 20.0 ± 0.2, and 21.6 ± 0.2.

### Claim 2 (depends on 1)

The crystalline Form A according to claim 1, characterized by an X-ray powder diffractogram having a signal at at least seven two-theta values chosen from 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 18.1 ± 0.2, 20.0 ± 0.2, 21.6 ± 0.2, 23.1 ± 0.2, 23.9 ± 0.2, 25.9 ± 0.2, and 30.7 ± 0.2.

### Claim 3 (depends on 1)

The crystalline Form A according to claim 1, characterized by an X-ray powder diffractogram having a signal at at least eight two-theta values chosen from 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 18.1 ± 0.2, 20.0 ± 0.2, 21.6 ± 0.2, 23.1 ± 0.2, 23.9 ± 0.2, 25.9 ± 0.2, and 30.7 ± 0.2.

### Claim 4 (depends on 1)

The crystalline Form A according to claim 1, characterized by an X-ray powder diffractogram having a signal at two-theta values of 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 18.1 ± 0.2, 20.0 ± 0.2, 21.6 ± 0.2, 23.1 ± 0.2, 23.9 ± 0.2, 25.9 ± 0.2, and 30.7 ± 0.2.

### Claim 5 (depends on 1)

The crystalline Form A according to claim 1, characterized by an X-ray powder diffractogram having a signal at two-theta values of 11.5 ± 0.2, 15.4 ± 0.2, 16.7 ± 0.2, 20.0 ± 0.2, and 21.6 ± 0.2.

### Claim 6 (depends on 1)

The crystalline Form A according to claim 1, characterized by a DSC thermogram having an endothermic event with a signal at a temperature ranging from 194 °C to 195 °C or an onset temperature of 193 °C.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising: at least one pharmaceutically acceptable excipient; and the crystalline Form A of Compound (I) according to claim 1.

### Claim 8 (depends on 1)

A method of treating mastocytosis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form A of Compound (I) according to claim 1.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the mastocytosis is selected from cutaneous mastocytosis (CM) and systemic mastocytosis (SM).

### Claim 10 (depends on 9)

The method according to claim 9, wherein the systemic mastocytosis is selected from indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), and advanced systemic mastocytosis (AdvSM).

### Claim 11 (depends on 10)

The method according to claim 10, wherein the systemic mastocytosis is advanced systemic mastocytosis (AdvSM).

### Claim 12 (depends on 11)

The method according to claim 11, wherein the crystalline Form A of Compound (I) is administered once daily in a therapeutically effective amount of 200 mg.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the systemic mastocytosis is indolent systemic mastocytosis (ISM).

### Claim 14 (depends on 13)

The method according to claim 13, wherein the crystalline Form A of Compound (I) is administered once daily in a therapeutically effective amount of 25 mg.

### Claim 15 (depends on 1)

A method of treating gastrointestinal stromal tumor, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form A according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the crystalline Form A of Compound (I) is administered once daily in a therapeutically effective amount of 300 mg.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the gastrointestinal stromal tumor is characterized by an exon 18 mutation in PDGFRα.

### Claim 18 (depends on 1)

A method of treating acute myeloid leukemia, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form A according to claim 1.

### Claim 19 (depends on 1)

A method of preparing the crystalline Form A of Compound (I) according to claim 1, comprising:
dissolving Compound (I) in a mixture of acetone and water to obtain a suspension;
heating the suspension to a temperature ranging from 40°C to 50°C to obtain a solution; and
cooling the solution.
